Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies

[Display omitted] •Pros and cons and recent trends of EVs for drug delivery in animal disease models.•Quantitative analysis of the key parameters of EVs as drug delivery systems.•EVs have unique niches for RNA delivery and vaccine development.•Preclinical data of EVs as drug delivery systems to inte...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews Vol. 175; p. 113801
Main Authors: Escudé Martinez de Castilla, Pol, Tong, Lingjun, Huang, Chenyuan, Sofias, Alexandros Marios, Pastorin, Giorgia, Chen, Xiaoyuan, Storm, Gert, Schiffelers, Raymond M., Wang, Jiong-Wei
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.08.2021
Subjects:
Animals
Clinical trial
Disease Models, Animal
Drug delivery
Drug Delivery Systems - methods
Extracellular vesicles
Extracellular Vesicles - metabolism
Liposomes
Preclinical animal models
Systematic review
Extracellular vesicles
Systematic review
Clinical trial
Drug delivery
Liposomes
Preclinical animal models
ISSN:0169-409X, 1872-8294, 1872-8294
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Pros and cons and recent trends of EVs for drug delivery in animal disease models.•Quantitative analysis of the key parameters of EVs as drug delivery systems.•EVs have unique niches for RNA delivery and vaccine development.•Preclinical data of EVs as drug delivery systems to interpret with caution.•Lack of regulatory guidelines for clinical research of EVs as drug delivery systems. During the past decades, extracellular vesicles (EVs) have emerged as an attractive drug delivery system. Here, we assess their pre-clinical applications, in the form of a systematic review. For each study published in the past decade, disease models, animal species, EV donor cell types, active pharmaceutical ingredients (APIs), EV surface modifications, API loading methods, EV size and charge, estimation of EV purity, presence of biodistribution studies and administration routes were quantitatively analyzed in a defined and reproducible way. We have interpreted the trends we observe over the past decade, to define the niches where to apply EVs for drug delivery in the future and to provide a basis for regulatory guidelines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0169-409X
1872-8294
1872-8294
DOI:10.1016/j.addr.2021.05.011